Neurocrine Biosciences

Our first-in-class treatment for individuals living with classic congenital adrenal hyperplasia is now available by prescription. Read more about our treatment and the Neurocrine Access Support program: https://lnkd.in/gTtcNG2w

At Neurocrine Biosciences, our foundational work began in neuroendocrine disorders, and the approval of our treatment for classic congenital adrenal hyperplasia has been over 30 years in the making. This milestone reflects our dedication to the CAH community as we bring to market the first and only treatment specifically developed for patients living with classic CAH. Read more: https://lnkd.in/ge_hpE8Q

Our treatment for classic congenital adrenal hyperplasia has been approved by the U.S. FDA for use in adults and children, ages 4 and older. It is a first-in-class treatment developed for individuals living with classic CAH and represents a significant shift in the treatment landscape. Learn more about the impact of this approval for the CAH community. https://lnkd.in/ge_hpE8Q

We were honored to be awarded the Hall of Fame Award at the ASCP Annual Meeting. The Hall of Fame Award recognizes an ASCP Corporate Partner for distinguished service and significant contributions to the profession. For Neurocrine, this reinforces our commitment to residents in long-term care settings. 

‘Tis the season to give thanks! Our events team put on a festive, holiday lunch for Thanksgiving at our headquarters. We are grateful for the hard work and dedication of our amazing team at Neurocrine. The contributions you make positively impact patients' lives, and we are truly thankful for all that you do. 

Recognized each November, National Native American Heritage Month commemorates the culture, traditions and achievements of Indigenous People. #NativeAmericanHeritageMonth

We were thrilled to host students from Charles R. Drew University of Medicine and Science's Biomedical Sciences Enrichment Program at our headquarters in San Diego! During the visit, the students met with a panel of employees, learned about our R&D labs and explored our summer internship program. Thank you, CDU students! 

We are proud to recognize Nurse Practitioner Week, which honors NPs for the fundamental and versatile roles they play on patient care teams. All Advanced Practice Providers, like NPs, can help improve the recognition, diagnosis and management of tardive dyskinesia by making screening a part of their clinical routine for all patients on dopamine receptor blocking agents. Read more about the importance of routine screening for TD in this article, sponsored by Neurocrine and published in the Psychiatric Times https://lnkd.in/g_T4nD7w

Today we presented subgroup analyses and data from the KINECT®-HD study evaluating the emotional health and psychiatric stability in patients with chorea associated with Huntington’s disease. https://lnkd.in/gGm_QzWk Huntington Study Group #HSG2024

As our newly appointed CEO, Kyle W. Gano, Ph.D., shared his enthusiasm for Neurocrine’s future on our Q3 2024 #EarningsCall. ICYMI, you can read the transcript here: https://lnkd.in/g6wZX4bQ $NBIX